About us
By integrating drug substance, drug product, and clinical testing activities, Translational Pharmaceutics® accelerates molecules through development. This saves time and money in reaching key milestones as quickly and efficiently as possible, ensuring better decision-making and more streamlined outsourcing.
Our expertise in understanding dependencies between drug substance properties, formulation design, and clinical outcomes enables us to enhance development efficiency.
By having both drug substance and drug product manufacturing activities under one organization, we can now deliver integrated chemistry, manufacturing, and controls (CMC) development activities for both pre-clinical and clinical studies in parallel, simplifying the supply chain and shortening the time from candidate selection to the clinic by a further 2–4 months.
Translational Pharmaceutics® has now been used by pharmaceutical and biotech companies on over 500 drug programs. The financial benefits and time savings were quantified in a publication by the Tufts Center for the Study of Drug Development.
The seamless coordination between drug substance and drug product manufacturing results in a more efficient and accelerated development plan. Integrating all activities under a single organization, and removing silos, encourages close relationships between multidisciplinary experts and creates a more agile approach to pharmaceutical development. Learn how a fully integrated program can speed up the transition from candidate selection to POC and shorten the pathway to clinical drug development.
It's common for most new drugs to require some sort of formulation change or optimization during their development, whether to respond to suboptimal exposure profiles, to transition from an early development formulation to one suitable for chronic administration, or as part of a life-cycle management strategy.
At Quotient Sciences, our unique approach to drug product optimization, using our integrated Translational Pharmaceutics platform, enables us to design, manufacture and obtain clinical data on new formulations in an accelerated timeframe all under a single organization. This approach saves significant time by reducing the CMC data package needed for your clinical assessments, maximizes flexibility in being able to fine-tune formulations, and conserves API.
Read our Translational Pharmaceutics® blog
In this latest blog written by Quotient Sciences' Senior Drug Development Consultant, Dr Aruna Railkar, she reviews some of our solubility-enhancement, modified-release, and pediatric case studies that required specialized formulation expertise.